Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
1999 2
2000 1
2001 1
2007 3
2008 1
2009 1
2010 6
2011 1
2013 1
2014 2
2018 4
2019 4
2020 4
2021 4
2022 3
2023 5
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Passaro A, et al. Among authors: mackean m. Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23. Ann Oncol. 2024. PMID: 37879444 Free article. Clinical Trial.
The National Lung Matrix Trial of personalized therapy in lung cancer.
Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L. Middleton G, et al. Among authors: mackean m. Nature. 2020 Jul;583(7818):807-812. doi: 10.1038/s41586-020-2481-8. Epub 2020 Jul 15. Nature. 2020. PMID: 32669708 Free PMC article. Clinical Trial.
Defining the road map to a UK national lung cancer screening programme.
O'Dowd EL, Lee RW, Akram AR, Bartlett EC, Bradley SH, Brain K, Callister MEJ, Chen Y, Devaraj A, Eccles SR, Field JK, Fox J, Grundy S, Janes SM, Ledson M, MacKean M, Mackie A, McManus KG, Murray RL, Nair A, Quaife SL, Rintoul R, Stevenson A, Summers Y, Wilkinson LS, Booton R, Baldwin DR, Crosbie P. O'Dowd EL, et al. Among authors: mackean m. Lancet Oncol. 2023 May;24(5):e207-e218. doi: 10.1016/S1470-2045(23)00104-3. Lancet Oncol. 2023. PMID: 37142382 Review.
Interventions for the treatment of borderline ovarian tumours.
Faluyi O, Mackean M, Gourley C, Bryant A, Dickinson HO. Faluyi O, et al. Among authors: mackean m. Cochrane Database Syst Rev. 2010 Sep 8;2010(9):CD007696. doi: 10.1002/14651858.CD007696.pub2. Cochrane Database Syst Rev. 2010. PMID: 20824864 Free PMC article. Review.
Understanding patient barriers and facilitators to uptake of lung screening using low dose computed tomography: a mixed methods scoping review of the current literature.
Cavers D, Nelson M, Rostron J, Robb KA, Brown LR, Campbell C, Akram AR, Dickie G, Mackean M, van Beek EJR, Sullivan F, Steele RJ, Neilson AR, Weller D. Cavers D, et al. Among authors: mackean m. Respir Res. 2022 Dec 23;23(1):374. doi: 10.1186/s12931-022-02255-8. Respir Res. 2022. PMID: 36564817 Free PMC article. Review.
How many cisplatin administration protocols does your department use?
Greystoke AP, Jodrell DI, Cheung M, Rivans I, Mackean MJ. Greystoke AP, et al. Among authors: mackean mj. Eur J Cancer Care (Engl). 2010 Jan 1;19(1):80-90. doi: 10.1111/j.1365-2354.2007.00908.x. Epub 2009 Aug 25. Eur J Cancer Care (Engl). 2010. PMID: 19708939 Review.
Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome.
Hollis RL, Thomson JP, Stanley B, Churchman M, Meynert AM, Rye T, Bartos C, Iida Y, Croy I, Mackean M, Nussey F, Okamoto A, Semple CA, Gourley C, Herrington CS. Hollis RL, et al. Among authors: mackean m. Nat Commun. 2020 Oct 5;11(1):4995. doi: 10.1038/s41467-020-18819-5. Nat Commun. 2020. PMID: 33020491 Free PMC article.
Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.
Stares M, Ding TE, Stratton C, Thomson F, Baxter M, Cagney H, Cumming K, Swan A, Ross F, Barrie C, Maclennan K, Campbell S, Evans T, Tufail A, Harrow S, Lord H, Laird B, MacKean M, Phillips I. Stares M, et al. Among authors: mackean m. ESMO Open. 2022 Apr;7(2):100445. doi: 10.1016/j.esmoop.2022.100445. Epub 2022 Apr 7. ESMO Open. 2022. PMID: 35398717 Free PMC article.
48 results